Skip to main content
Bafna Pharmaceuticals Limited logo

Bafna Pharmaceuticals Limited — Investor Relations & Filings

Ticker · BAFNAPH ISIN · INE878I01022 LEI · 984500D03E2C7Y5EE587 BSE.NS Manufacturing
Open in API
Filings indexed 244 across all filing types
Latest filing 2025-11-11 Regulatory Filings
Country IN India
Listing BSE.NS BAFNAPH

About Bafna Pharmaceuticals Limited

http://bafnapharma.com/

Bafna Pharmaceuticals Limited specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities certified by WHO-GMP standards, ensuring high-quality production of finished dosage forms including tablets, capsules, syrups, and suspensions. Its therapeutic portfolio spans multiple categories such as anti-infectives, analgesics, cardiovascular, gastrointestinal, and vitamins. The organization serves both domestic and international markets, with a significant presence in emerging regions across Africa, Southeast Asia, and the CIS. In addition to its proprietary product line, the company provides comprehensive contract manufacturing and formulation development services, leveraging its technical expertise and regulatory compliance to meet global healthcare requirements.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2025-11-11 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-11-06 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a formal letter from Bafna Pharmaceuticals Limited addressed to stock exchanges, notifying about an upcoming Board Meeting scheduled for November 11, 2025. The purpose of the meeting is to consider and approve the Un-Audited Financial Results for the quarter and half year ended September 30, 2025. The letter also mentions the closure of the trading window for insiders during this period. The document is an announcement of a Board Meeting and does not contain the actual financial results or detailed financial data. It is a regulatory compliance communication under SEBI (LODR) Regulations, 2015, informing about the meeting date and agenda. Given the content and length (2089 characters), this is not the financial report itself but an announcement related to management activity and regulatory compliance. Therefore, the most appropriate classification is Board/Management Information (MANG).
2025-11-06 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2025. It is a compliance certificate issued by the Registrar and Share Transfer Agent confirming dematerialisation and listing of securities. The document is short (3279 characters) and is a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory compliance documents and certifications.
2025-10-10 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges announcing the closure of the trading window for insiders due to the upcoming declaration of un-audited financial results for the quarter ending September 30, 2025. It references regulatory compliance with SEBI (Prohibition of Insider Trading) Regulations and specifies the trading window closure period. The document does not contain any financial data, results, or detailed report content but is an announcement related to trading restrictions ahead of a financial report release. Therefore, it is not an Interim/Quarterly Report (IR) or Earnings Release (ER) but an announcement related to insider trading restrictions. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance announcement without substantive financial data or report content.
2025-09-26 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, regarding the appointment and re-appointment of Independent Directors of Bafna Pharmaceuticals Limited. It includes detailed profiles and terms of appointment for three directors. The document is addressed to stock exchanges and references compliance with SEBI regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses exclusively on changes in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length (9668 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2025-09-19 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.